Hemlibra 105 mg Injection 0.7 ml

Hemlibra 105 mg Injection 0.7 ml is used to prevent or reduce bleeding episodes in individuals with haemophilia A. Haemophilia A is a genetic bleeding disorder caused by a deficiency or absence of clotting factor VIII that impairs blood clotting ability. It leads to prolonged bleeding episodes, often following injuries or surgeries, and can cause spontaneous internal bleeding.

Hemlibra 105 mg Injection 0.7 ml contains Emicizumab, which works by replicating the function of factor VIII, a crucial protein for blood clotting. It connects activated factor IX and factor X, promoting effective clot formation in individuals with haemophilia A. This process helps prevent and minimize bleeding episodes, including in patients with factor VIII inhibitors.

The dose and duration of treatment with Hemlibra 105 mg Injection 0.7 ml may vary depending on your medical condition. The common side effects of Hemlibra 105 mg Injection 0.7 ml include redness, tenderness, warmth, or itching at the injection site, as well as joint pain and headache. Most of these side effects resolve gradually over time. However, consult the doctor if any of these persist or worsen.

Inform your doctor if you are pregnant or planning pregnancy or breastfeeding before treatment with Hemlibra 105 mg Injection 0.7 ml. Hemlibra 105 mg Injection 0.7 ml is safe for children if prescribed by the doctor. Avoid alcohol consumption while taking Hemlibra 105 mg Injection 0.7 ml to prevent unpleasant side effects. Hemlibra 105 mg Injection 0.7 ml may cause dizziness; therefore, avoid driving or operating heavy machinery unless fully alert. Inform your doctor about all the medicines you are taking and about your pre-existing health conditions.

Hemlibra 105 mg Injection 0.7 ml is used to prevent or reduce bleeding episodes in individuals with haemophilia A (a genetic bleeding disorder). The detailed uses of Hemlibra 105 mg Injection 0.7 ml are as follows:

• Treatment of Hemophilia A:Hemlibra 105 mg Injection 0.7 ml is used in patients with factor VIII deficiency, reducing the frequency of spontaneous bleeding episodes.
• Prevention of Bleeding Episodes:Hemlibra 105 mg Injection 0.7 ml helps stabilize clot formation, preventing excessive bleeding in hemophilia A patients and reduces the need for frequent factor VIII infusions, improving quality of life.

• Follow your doctor's instructions on the dosage and timing of this medication.
• Hemlibra 105 mg Injection 0.7 ml is to be used under medical supervision. With proper training in subcutaneous injection, patients may be allowed to administer it themselves.
• Hemlibra 105 mg Injection 0.7 ml should not be injected into red or bruised areas.

Hemlibra 105 mg Injection 0.7 ml contains Emicizumab, which belongs to a group of medications called Monoclonal antibodies. It is used to prevent or reduce bleeding episodes in individuals with haemophilia A (a genetic bleeding disorder). Hemlibra 105 mg Injection 0.7 ml replicates the function of factor VIII, a crucial protein for blood clotting. It connects activated factor IX and factor X, promoting effective clot formation in individuals with haemophilia A. This process helps prevent and minimize bleeding episodes, including in patients with factor VIII inhibitors.

Inform your doctor if you are using factor VIII or a bypassing agent, as these may increase the risk of blood clots, particularly when combined with activated prothrombin complex concentrate (aPCC). You may need to stop using bypassing agents or adjust their dosage as instructed by your doctor. Also, inform your doctor about any pre-existing medical conditions and all medications you are taking, including over-the-counter drugs, vitamins, and herbal supplements. Let your doctor know if you are pregnant or planning to become pregnant.